Patients characteristics, n | All patients, 61 |
---|---|
Gender, male/female n (%) | 39/22 (64/36) |
Age, all patients, m (SD) | 61.9 (12.3) |
Family situation, n (%) | |
Married/cohabitant | 35 (57) |
Partner and children | 11 (18) |
Single parent | 3 (5) |
Single | 12 (20) |
Education, n (%) | |
Elementary school | 15 (25) |
High school | 24 (39) |
University | 22 (36) |
Occupational status, n, (%) | |
Working full-time | 6 (10) |
Working part-time | 5 (8) |
Sickness benefit fulltime | 17 (28) |
Retired | 31 (51) |
Unemployed | 1 (2) |
Other | 1 (2) |
Diagnosis, n (%) | |
ALSa | 31 (51) |
MNDb | 23 (38) |
PLSc | 7 (12) |
Time since first symptom of disease, m year (std) | 5,8 (7.2) |
Pain, BPI-SFd, n = 55 | |
Pain, n = yes (%) | 41 (74) |
Pain during past 24 h, n = yes (%) | 39 (71) |
Worst level of pain, md (IQR) | 5.0 (4.5) |
PSI, n = 41, m (std) | 3,8 (2,4) |
Neuropathic pain, n (%), DN4e | 12 (20) |
Chronic pain before onset of MND, n (%) | 22 (36) |
Disease severity, ALSFRS-Rf, md (Q1-Q3) | |
The bulbar function | 10 (7,5-12) |
The fine motor function | 8 (4-10) |
The gross motor function | 7 (5-9) |
The respiratory function | 12 (10-12) |
Drugsg, n (%) | |
Analgetics | 6 (10) |
Antidepressants | 17 (28) |
Antiepileptics | 2 (3) |
Anxiolytics | 9 (15) |
Hypnotics | 16 (26) |
NSAID | 8 (13) |
Opioids | 7 (12) |
Spasmolytics | 6 (10) |
Triptans | 2 (3) |
Riluzole | 55 (90) |
Nothing | 2 (3) |